Company / Return on Assets (ROA)
Intellia Therapeutics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-49.0%
FY2025
5-year range
-49.0% / -7.7%
FY2021-FY2025
Trend
-12.5%
vs FY2024
Sector context
#156 of 159
Health Care
What the data says
Among 159 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 2% for return on assets (roa). Return on Assets (ROA) has declined for 4 consecutive years, from -7.7% in FY2021 to -49.0% in FY2025.
Based on SEC 10-K filings.
-49.0% in FY2025 with a 5-year CAGR of -29.2%.
Declined from -37.0% to -49.0% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -17.8pp
- 5-Year Change
- -29.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 159This company -49.0% Sector average -2.2%
▼
-2115.8% below sector average
Key checks
Key Insights
- Intellia Therapeutics, Inc.'s return on assets (roa) has declined for 4 consecutive years.
- In FY2025, return on assets (roa) decreased 12.5% year-over-year.
- Currently 46.8pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -49.0% | -12.5% |
| FY2024 | -43.6% | -17.8% |
| FY2023 | -37.0% | -18.6% |
| FY2022 | -31.2% | -305.6% |
| FY2021 | -7.7% | +61.3% |
| FY2020 | -19.9% | +1.8% |
| FY2019 | -20.2% | -121.8% |
| FY2018 | -9.1% | +49.2% |
| FY2017 | -17.9% | -69.7% |
| FY2016 | -10.6% | +29.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026